Home » Topics » BioWorld Science

BioWorld Science
RSS

New ASK1/TAK1 dual kinase inhibitor for treating NASH presented

Nov. 20, 2019

Scholar Rock reports preliminary PK and PD data from phase II study of SRK-015 in SMA

Nov. 20, 2019

Phase III dosing defined for lixivaptan in autosomal dominant polycystic kidney disease

Nov. 20, 2019

Phase III study of vericiguat in worsening chronic heart failure meets primary endpoint

Nov. 20, 2019

COR-001 suppresses hsCRP in patients with chronic kidney disease

Nov. 20, 2019

DWP-212525, a next-generation therapeutic for autoimmune diseases

Nov. 20, 2019

Celldex begins phase Ia study with KIT inhibitor CDX-0159

Nov. 20, 2019

Haplodeficiency disrupts microglial responses in AD models

Nov. 20, 2019

RQ-00490721 prevents cardiac dysfunction in mouse model of heart failure

Nov. 20, 2019

Seviprotimut-L demonstrates safety and efficacy in part B1 of MAVIS phase III study

Nov. 20, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...